The most useful starting point for a cancer-vaccine trial search is a named product and a traceable study identifier—not a promise that a “cancer vaccine” is available. NCI provides a trial-search service and individual protocol records. A record can identify the research without proving that a nearby site has an open place or that a particular person qualifies. 1
This is a guide to interpreting official records. It does not enroll participants, assess medical eligibility or sell treatment access.
Use the trial identifier to avoid the wrong study
One product may appear under several names and in more than one protocol. For the melanoma program discussed in this edition, KEYNOTE-942 is NCT03897881; INTerpath-001 is NCT05933577. They are not the same trial. 2 3
A search result using an older program code may still be relevant. What matters is whether the identifier, clinical population and study description match the result you are trying to understand.
Keep these fields together in a reading note: official identifier, product names, disease setting, sponsor, source date and source URL. That prevents a later news article from being mistaken for a newly opened study.
An actual example: publication is not recruitment
The NCI listing for KEYNOTE-942 was marked closed to accrual when checked on September 17, 2026. It still contains valuable information about the study and links its ClinicalTrials.gov identifier. 2
A new follow-up analysis does not mean that trial is accepting new participants. Conversely, a study may be conducting visits and collecting outcomes after recruitment ends.
For a different illustration, NCI-2025-00334 was listed as active and described an individualized peptide-vaccine investigation across specified cancer cohorts. That listing is not the same as a confirmed open enrollment slot at a given institution. It also is not an mRNA-4157 study. 4
These examples show why “active,” “recruiting,” “published” and “available” should not be treated as synonyms. Current status must remain attached to the exact protocol and observation date.
Why cancer type alone is not enough
Eligibility can depend on the exact stage, prior treatment, timing after surgery, tumor testing, organ function and other requirements. The KEYNOTE-942 and peptide-vaccine records contain substantially more information than a broad label such as melanoma. 2 4
Use the public record to identify a potentially relevant protocol for discussion with the treating team. Do not turn a simplified online checklist into a medical eligibility decision. A person can appear to match the headline disease but not the actual study requirements.
A registry also is not a booking system. Only the relevant study team can explain its current sites, screening process and availability; an unrelated directory cannot supply that confirmation by copying the record.
Does trial participation mean the treatment is proven?
No. The purpose of clinical research is to answer unresolved questions under a defined protocol. A Phase 1 study, for example, should not be presented as an already demonstrated alternative simply because an institution is conducting it. 5
The earlier pancreatic-vaccine research and the later follow-up illustrate why a promising program can remain investigational while producing important evidence.
No article here should be used as a reason to stop established care or delay a medical discussion while waiting for a speculative release date.
Are cancer-vaccine trials free?
Do not assume that every expense is covered. NCI distinguishes research costs from routine patient-care costs and discusses the role of insurers and sponsors. Travel, lodging and other expenses can also require separate arrangements. Those details depend on the actual study and circumstances. 6
Consequently, this page supplies no universal vaccine-trial price, reimbursement promise or estimate of personal out-of-pocket cost. Before agreeing to participate, the relevant study and care teams should explain which costs belong to which party.
A fee paid to an unrelated website does not establish eligibility, enrollment or access to the studied product. This publication’s optional educational materials are not treatment-access services.
A source-first route through the information
Read the current program report or cancer-vaccine guide to identify the intervention and evidence. Then follow the official source record and its protocol identifier, rather than an advertisement that cannot name the study.
The outcome of that process is a better-informed conversation, not a guaranteed place in research. Preserve the distinction and a trial listing becomes useful without being transformed into an unsupported medical offer.
Access and payment are separate questions
Read clinical-trial costs for the difference between sponsor-funded research, routine care and travel. Expanded access versus a trial explains the separate US route without promising supply or personal eligibility.